Elevated glycosylated hemoglobin in diabetic neuropathy

Area of Science:

• Neurology
• Endocrinology
• Metabolic Disorders

Background:

• Symptomatic neuropathy affects numerous patients, with its underlying causes often linked to metabolic dysregulation.
• Established neuropathy requires objective diagnostic criteria, including nerve conduction studies and sensory threshold measurements.

Purpose of the Study:

• To investigate the association between glycosylated hemoglobin (GHb) levels and established symptomatic neuropathy.
• To determine if hyperglycemia, as indicated by GHb, plays a significant role in the pathophysiology of neuropathy.

Main Methods:

• GHb levels were measured in 36 patients with symptomatic neuropathy (duration ≥ 12 months) and 36 matched controls.
• Neuropathy diagnosis was confirmed using motor conduction velocities and vibration perception threshold.
• A semi-automated colorimetric assay utilizing thiobarbituric acid and 5-hydroxy-methyl furfural was employed for GHb estimation.

Main Results:

• Patients with neuropathy exhibited significantly higher GHb levels (58.2 ± 11.3 mmol HMF/mol Hb) compared to controls (50.0 ± 8.9 mmol HMF/mol Hb).
• The difference in GHb levels between the groups was statistically significant (p < 0.01).

Conclusions:

• Elevated GHb levels are strongly associated with established symptomatic neuropathy.
• Hyperglycemia and related metabolic abnormalities are likely critical contributing factors in the development and progression of neuropathy.